Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Basal Cell Nevus Syndrome Gorlin syndrome Basal cell nevus syndrome BCNS Nevoid basal cell carcinoma syndrome Basal cell carcinoma Hedgehog Surgically eligible basal cell carcinomas Patidegib Carcinoma Carcinoma, Basal Cell Nevus Nevus, Pigmented Syndrome Veratrum Alkaloids Patidegib Topical Gel, 2% Patidegib Topical Gel, Vehicle Patidegib Topical Gel, 2%,
Lead Scientist at UCSF
- Siegrid Yu
Professor, Dermatology. Authored (or co-authored) 61 research publications.
- in progress, not accepting new patients
- Start Date
- Completion Date
- PellePharm, Inc.
- Phase 3
- Study Type
- Last Updated